Compare NEOG & ETV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NEOG | ETV |
|---|---|---|
| Founded | 1981 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 1995 | 2005 |
| Metric | NEOG | ETV |
|---|---|---|
| Price | $11.64 | $15.10 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $10.67 | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 148.0K |
| Earning Date | 04-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.20 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $870,400,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.90 | $13.13 |
| 52 Week High | $12.85 | $15.33 |
| Indicator | NEOG | ETV |
|---|---|---|
| Relative Strength Index (RSI) | 56.74 | 50.68 |
| Support Level | $8.86 | $14.22 |
| Resistance Level | $12.85 | $15.32 |
| Average True Range (ATR) | 0.39 | 0.16 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 42.34 | 36.24 |
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of common stocks, designated segments of which seek to exceed the total return performance of the S&P 500 and the NASDAQ-100.